Selective internal radiation therapy (SIRT) before partial hepatectomy or radiofrequency destruction for treatment of hepatocellular carcinoma in cirrhotic patients: a feasibility and safety pilot study.

[1]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[2]  W. Lau,et al.  The Post-SIR-Spheres Surgery Study (P4S): Retrospective Analysis of Safety Following Hepatic Resection or Transplantation in Patients Previously Treated with Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres , 2017, Annals of Surgical Oncology.

[3]  A. Rademaker,et al.  Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. , 2016, Gastroenterology.

[4]  C. Peng,et al.  Preoperative transarterial chemoembolization for resectable hepatocellular carcinoma in Asia area: a meta-analysis of random controlled trials , 2016, Scandinavian journal of gastroenterology.

[5]  M. Abecassis,et al.  90Y radiation lobectomy: Outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes , 2016, Journal of surgical oncology.

[6]  Jeong Won Lee,et al.  Prognostic Significance of 18F-FDG Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent Chemoradiotherapy: A Multicenter Retrospective Cohort Study , 2016, The Journal of Nuclear Medicine.

[7]  M. Makuuchi,et al.  Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. , 2015, The Lancet. Oncology.

[8]  P. Flamen,et al.  Radioembolisation and portal vein embolization before resection of large hepatocellular carcinoma. , 2015, World journal of gastroenterology.

[9]  K. Tatsch,et al.  Liver resection after selective internal radiotherapy (SIRT): Proof of concept, initial survival, and safety , 2015, Journal of surgical oncology.

[10]  A. Russo,et al.  Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis , 2015, PloS one.

[11]  O. Shibolet,et al.  [18F]fludeoxyglucose positron emission tomography and computed tomography as a prognostic tool before liver transplantation, resection, and loco‐ablative therapies for hepatocellular carcinoma , 2015, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[12]  A. Luciani,et al.  Liver resection for hepatocellular carcinoma in 313 Western patients: tumor biology and underlying liver rather than tumor size drive prognosis. , 2015, Journal of hepatology.

[13]  T. Nishidate,et al.  Comprehensive review of post-liver resection surgical complications and a new universal classification and grading system. , 2014, World journal of hepatology.

[14]  J. Bruix,et al.  Treatment of intermediate-stage hepatocellular carcinoma , 2014, Nature Reviews Clinical Oncology.

[15]  A. Darzi,et al.  Laparoscopic vs open approach to resection of hepatocellular carcinoma in patients with known cirrhosis: systematic review and meta-analysis. , 2014, World journal of gastroenterology.

[16]  M. Abecassis,et al.  Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. , 2013, Journal of hepatology.

[17]  Carlo Morosi,et al.  Yttrium‐90 radioembolization for intermediate‐advanced hepatocellular carcinoma: A phase 2 study , 2013, Hepatology.

[18]  K. Boudjema,et al.  Volumetric Changes after 90Y Radioembolization for Hepatocellular Carcinoma in Cirrhosis: An Option to Portal Vein Embolization in a Preoperative Setting? , 2013, Annals of Surgical Oncology.

[19]  P. Chow,et al.  Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria , 2012, The British journal of surgery.

[20]  B. Sangro,et al.  Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma. , 2012, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[21]  K. Okazaki,et al.  A Prospective Randomized Controlled Trial of Preoperative Whole-Liver Chemolipiodolization for Hepatocellular Carcinoma , 2012, Digestive Diseases and Sciences.

[22]  Riccardo Lencioni,et al.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. , 2012, Journal of hepatology.

[23]  F. Izzo,et al.  Survival after yttrium‐90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation , 2011, Hepatology.

[24]  M. Schwartz,et al.  Second hepatic resection for recurrent hepatocellular cancer: a Western experience. , 2011, Journal of hepatology.

[25]  K. McMasters,et al.  Safety of hepatic resection in metastatic disease to the liver after yttrium-90 therapy. , 2011, The Journal of surgical research.

[26]  A. Benson,et al.  Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. , 2011, Gastroenterology.

[27]  K. McMasters,et al.  Hepatectomy after hepatic arterial therapy with either yttrium-90 or drug-eluting bead chemotherapy: is it safe? , 2011, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[28]  L. Schwartz,et al.  Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Abecassis,et al.  A Comparative Analysis of Transarterial Downstaging for Hepatocellular Carcinoma: Chemoembolization Versus Radioembolization , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[30]  M. Abecassis,et al.  Radiation Lobectomy: Preliminary Findings of Hepatic Volumetric Response to Lobar Yttrium-90 Radioembolization , 2009, Annals of Surgical Oncology.

[31]  G. Cabibbo,et al.  Multimodal approaches to the treatment of hepatocellular carcinoma , 2009, Nature Clinical Practice Gastroenterology &Hepatology.

[32]  W. Lau,et al.  A Prospective, Randomized, Controlled Trial of Preoperative Transarterial Chemoembolization for Resectable Large Hepatocellular Carcinoma , 2009, Annals of surgery.

[33]  Y. Fong,et al.  Preoperative Y-90 microsphere selective internal radiation treatment for tumor downsizing and future liver remnant recruitment: a novel approach to improving the safety of major hepatic resections , 2009, World journal of surgical oncology.

[34]  D. Larsimont,et al.  Inducing resectability of chemotherapy refractory colorectal liver metastasis by radioembolization with yttrium-90 microspheres. , 2008, Clinical nuclear medicine.

[35]  M. Abecassis,et al.  Yttrium‐90 microspheres (TheraSphere®) treatment of unresectable hepatocellular carcinoma: Downstaging to resection, RFA and bridge to transplantation , 2006, Journal of surgical oncology.

[36]  N. Demartines,et al.  Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey , 2004, Annals of Surgery.

[37]  M. Makuuchi,et al.  Selection Criteria for Repeat Hepatectomy in Patients With Recurrent Hepatocellular Carcinoma , 2003, Annals of surgery.

[38]  H. Hsu,et al.  Surgical resection for recurrent hepatocellular carcinoma: prognosis and analysis of risk factors. , 1996, Surgery.

[39]  F. P'eng,et al.  Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: A reappraisal , 1995, The British journal of surgery.